Hodgkin's Lymphoma News and Research

Latest Hodgkin's Lymphoma News and Research

Ibrutinib continues to show unprecedented results in patients with mantle cell lymphoma

An international study of ibrutinib in people with relapsed or refractory mantle cell lymphoma (MCL) continues to show unprecedented and durable results with few side effects.

15 Dec 2012

Final data from Aeterna Zentaris’ perifosine plus sorafenib Phase 2 study on lymphomas

Aeterna Zentaris Inc. today announced that final Phase 2 data demonstrated that the combination of perifosine, its oral AKT inhibitor, and sorafenib, was well tolerated by heavily pretreated patients with relapsed/refractory lymphomas.

12 Dec 2012

Study finds high serum galectin-1 levels in Hodgkin lymphoma patients

Blood levels of an immunity-related protein, galectin-1, in patients with newly diagnosed Hodgkin lymphoma reflected the extent of their cancer and correlated with other predictors of outcome, scientists reported at the American Society of Hematology annual meeting.

11 Dec 2012

Weill Cornell research team develops new experimental drug therapy to target DLBCL

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin's lymphoma and the seventh most frequently diagnosed cancer. The most chemotherapy resistant form of DLBCL, called activated B-cell - DLBCL (ABC-DLBCL), remains a major therapeutic challenge.

11 Dec 2012

Celgene announces results from REVLIMID plus VIDAZA phase II study on AML

Celgene International Sàrl today announced that results from a study evaluating the combination of REVLIMID (lenalidomide) plus VIDAZA (azacitidine) in patients 60 years or older with untreated acute myeloid leukemia (AML) were presented at the American Society of Hematology annual meeting in Atlanta, GA.

11 Dec 2012

Infinity announces new data from IPI-145 Phase 1 trial on advanced hematologic malignancies

Infinity Pharmaceuticals, Inc. today announced new data from its ongoing Phase 1, open-label, dose-escalation trial of IPI-145, the company's potent, oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, in patients with advanced hematologic malignancies.

11 Dec 2012

Epizyme to present data from DOT1L and EZH2 inhibitor programs at 54th ASH annual meeting

Epizyme, Inc., a biopharmaceutical company leading the creation of personalized therapeutics to treat patients with genetically defined cancers, today announced the presentation of data evaluating the preclinical safety and efficacy of two of the Company's novel, potent and selective small molecule inhibitors. These inhibitors individually target DOT1L and EZH2, members of a class of epigenic enzymes called histone methyltransferases (HMTs).

30 Nov 2012

Gabrielle's Angel Foundation announces recipients of new collaborative grants for cancer research

Gabrielle's Angel Foundation for Cancer Research today announced grant recipients of its first-ever Collaborative Research grant program. The inaugural awards total $800,000 for two groundbreaking research initiatives that span the medical capitals of New York, Boston and Chicago.

21 Nov 2012

CD22 protein could prove to be important new target for anti-cancer therapy

A team of UC Davis investigators has discovered a protein on the surface of lung cancer cells that could prove to be an important new target for anti-cancer therapy. A series of experiments in mice with lung cancer showed that specific targeting of the protein with monoclonal antibodies reduced the size of tumors, lowered the occurrence of metastases and substantially lengthened survival time.

2 Nov 2012

EC grants conditional marketing authorisation for ADCETRIS to treat hematological cancers

Takeda Pharmaceutical Company Limited and Millennium: The Takeda Oncology Company, today announced that the European Commission has granted conditional marketing authorisation for ADCETRIS (brentuximab vedotin) for two indications.

31 Oct 2012

Symposium to discuss latest scientific and clinical advances in treating non-Hodgkins lymphoma

Fifty world-renowned experts in non-Hodgkins lymphoma will convene in New York in November to present the latest scientific and clinical advances in treating a "lost generation" of sufferers-children, young adults and adolescents.

31 Oct 2012

Night work can increase risk of cancer in men

Night work can increase cancer risk in men, according to a new study published in the American Journal of Epidemiology by a research team from Centre INRS-Institut Armand-Frappier and Centre de recherche du Centre hospitalier de l'Universit- de Montr-al.

16 Oct 2012

University of Iowa, Mayo Clinic to continue SPORE for lymphoma research

The Mayo Clinic Cancer Center and Holden Comprehensive Cancer Center at the University of Iowa have received a five-year, $11.5 million grant renewal from the National Cancer Institute (NCI) to continue the Specialized Program of Research Excellence (SPORE) for lymphoma research.

25 Sep 2012

$Encouraging results from CTI’s pacritinib phase 1 study on relapsed/refractory lymphoma$

Encouraging results from CTI’s pacritinib phase 1 study on relapsed/refractory lymphoma

Cell Therapeutics, Inc. announced today that the phase 1 study data of its highly selective oral JAK2 inhibitor pacritinib, or SB1518, showed encouraging anti-tumor activity and good tolerability in 34 patients with relapsed/refractory lymphoma.

24 Sep 2012

Biovest seeks EMA approval for BiovaxID to treat non-Hodgkin's lymphoma

Biovest International, Inc., a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc., today reported milestone achievements advancing BiovaxID, Biovest's personalized cancer vaccine for the treatment of non-Hodgkin's lymphoma, including a recently conducted regulatory meeting with the European Medicines Agency (EMA) and the appointment of a key contributor to the Human Genome Project to its Scientific Advisory Board.

21 Sep 2012

Cell Therapeutics launches Pixuvri in the European Union

Cell Therapeutics, Inc., a company focused on translating science into novel cancer therapies, today announced the initiation of the commercial launch of Pixuvri in the European Union with entry into Sweden, Denmark and Finland in September, to be followed by Austria and Norway in early October 2012 and Germany, United Kingdom and the Netherlands in November 2012.

11 Sep 2012

Longer looks: Insurers balk at price of new asthma relief; Despite health law, costs still overwhelming for some patients

For two decades, Patricia DiGiusto struggled with severe asthma. Powerful medications and frequent use of her inhaler could not prevent repeated trips to the emergency room. ... Two years ago, Ms. DiGiusto's doctor told her about a new procedure called bronchial thermoplasty, the first non-drug therapy approved by the Food and Drug Administration for patients with severe asthma.

7 Sep 2012

Sicor Biotech receives FDA approval for tbo-filgrastim to treat severe neutropenia

The U.S. Food and Drug Administration today approved Sicor Biotech's tbo-filgrastim to reduce the time certain patients receiving cancer chemotherapy experience severe neutropenia, a decrease in infection-fighting white blood cells called neutrophils.

30 Aug 2012

Radiation therapy alone no longer the best choice for early follicular lymphoma

A University of Rochester Medical Center study published in the Journal of Clinical Oncology, challenges treatment guidelines for early stage follicular lymphoma, concluding that six different therapies can bring a remission, particularly if the patient is carefully examined and staged at diagnosis.

22 Aug 2012

FDA requests Biovest to conduct second Phase III trial of BV301 for NHL

Biovest International, Inc., a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc., today announced that it conducted a formal clinical guidance meeting with the U.S. FDA to determine the most expeditious U.S. registration pathway for BiovaxID, its personalized cancer vaccine for the consolidation treatment of follicular non-Hodgkin's lymphoma.

15 Aug 2012

Hodgkin's Lymphoma News and Research

Latest Hodgkin's Lymphoma News and Research

Ibrutinib continues to show unprecedented results in patients with mantle cell lymphoma

Final data from Aeterna Zentaris’ perifosine plus sorafenib Phase 2 study on lymphomas

Study finds high serum galectin-1 levels in Hodgkin lymphoma patients

Weill Cornell research team develops new experimental drug therapy to target DLBCL

Celgene announces results from REVLIMID plus VIDAZA phase II study on AML

Infinity announces new data from IPI-145 Phase 1 trial on advanced hematologic malignancies

Epizyme to present data from DOT1L and EZH2 inhibitor programs at 54th ASH annual meeting

Gabrielle's Angel Foundation announces recipients of new collaborative grants for cancer research

CD22 protein could prove to be important new target for anti-cancer therapy

EC grants conditional marketing authorisation for ADCETRIS to treat hematological cancers

Symposium to discuss latest scientific and clinical advances in treating non-Hodgkins lymphoma

Night work can increase risk of cancer in men

University of Iowa, Mayo Clinic to continue SPORE for lymphoma research

Encouraging results from CTI’s pacritinib phase 1 study on relapsed/refractory lymphoma

Biovest seeks EMA approval for BiovaxID to treat non-Hodgkin's lymphoma

Cell Therapeutics launches Pixuvri in the European Union

Longer looks: Insurers balk at price of new asthma relief; Despite health law, costs still overwhelming for some patients

Sicor Biotech receives FDA approval for tbo-filgrastim to treat severe neutropenia

Radiation therapy alone no longer the best choice for early follicular lymphoma

FDA requests Biovest to conduct second Phase III trial of BV301 for NHL

Everything you should know about lymphoma eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Hodgkin's Lymphoma News and Research

Latest Hodgkin's Lymphoma News and Research

Everything you should know about lymphoma eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in